UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

PloS one, 2010-02, Vol.5 (2), p.e9001

2010

Volltextzugriff (PDF)

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences

British journal of haematology, 2012-10, Vol.159 (2), p.154-163

2012

Volltextzugriff (PDF)

Design, Structure−Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors

Journal of medicinal chemistry, 2009-01, Vol.52 (2), p.278-292

2009

Volltextzugriff (PDF)

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-04, Vol.14 (7), p.2075-2081

2008

Volltextzugriff (PDF)

Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells

Cancer science, 2011-06, Vol.102 (6), p.1201-1207

2011

Volltextzugriff (PDF)

In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Clinical cancer research, 2005-05, Vol.11 (10), p.3633-3641

2005

Volltextzugriff (PDF)

A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer

Clinical cancer research, 2000-03, Vol.6 (3), p.798

2000

Volltextzugriff (PDF)

CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice

Clinical cancer research, 2006-08, Vol.12 (16), p.4908-4915

2006

Volltextzugriff (PDF)

CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia

Clinical cancer research, 2005-07, Vol.11 (14), p.5281-5291

2005

Volltextzugriff (PDF)

Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration

Clinical cancer research, 2000-12, Vol.6 (12), p.4908-4914

2000

Volltextzugriff (PDF)

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy

Cancer research (Chicago, Ill.), 2000-03, Vol.60 (5), p.1193-1196

2000

Volltextzugriff (PDF)

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy

Cancer research (Chicago, Ill.), 1999-06, Vol.59 (11), p.2623-2628

1999

Volltextzugriff (PDF)

Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression

British journal of haematology, 2013-02, Vol.160 (4), p.487-502

2013

Volltextzugriff (PDF)

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects

Cancer gene therapy, 1999-11, Vol.6 (6), p.499-504

1999

Volltextzugriff (PDF)

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

Clinical cancer research, 2015-11, Vol.21 (21), p.4811-4818

2015

Volltextzugriff (PDF)

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

British journal of haematology, 2014-06, Vol.165 (6), p.870-882

2014

Volltextzugriff (PDF)

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma

Journal of immunotherapy, 2007-01, Vol.30 (1), p.64-74

2007

Volltextzugriff (PDF)

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer

British journal of cancer, 2016-08, Vol.115 (4), p.442-453

2016

Volltextzugriff (PDF)

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

Blood, 2005-04, Vol.105 (7), p.2941-2948

2005

Volltextzugriff (PDF)

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

Nature medicine, 2000-10, Vol.6 (10), p.1134-1139

2000

Volltextzugriff (PDF)

The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism

British journal of haematology, 2010-11, Vol.151 (4), p.387-396

2010

Volltextzugriff (PDF)

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints

Cancer research (Chicago, Ill.), 2002-11, Vol.62 (21), p.6070-6079

2002

Volltextzugriff (PDF)

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

Expert review of anticancer therapy, 2010-10, Vol.10 (10), p.1663-1672

2010

Volltextzugriff (PDF)

Replication-selective adenoviruses as oncolytic agents

The Journal of clinical investigation, 2000-04, Vol.105 (7), p.847-851

2000

Volltextzugriff (PDF)

Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors

Bioorganic & medicinal chemistry letters, 2015-06, Vol.25 (12), p.2514-2518

2015

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(75)
Dissertationen
(1)

Sprache

Englisch
(76)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(43)
Humans
(35)
Animals
(26)
Female
(26)
Biological And Medical Sciences
(24)
Medical Sciences
(23)
Mice
(18)
Oncology
(17)
Antineoplastic Agents
(13)
Male
(12)
Pharmacology. Drug Treatments
(12)
Tumors
(9)
Cell Line, Tumor
(8)
Hematologic And Hematopoietic Diseases
(8)
Mice, Nude
(8)
Tumor Cells, Cultured
(8)
In Situ Hybridization
(7)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(7)
Mutation
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences

Design, Structure−Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells

In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer

CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice

CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia

Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy

Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

Replication-selective adenoviruses as oncolytic agents

Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors

Suchergebnisse filtern